Zidesamtinib (NVL-520)
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced Solid Tumor
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Trial Timeline
Jan 4, 2022 → Dec 31, 2028
NCT ID
NCT05118789About Zidesamtinib (NVL-520)
Zidesamtinib (NVL-520) is a phase 1/2 stage product being developed by Nuvalent for Locally Advanced Solid Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05118789. Target conditions include Locally Advanced Solid Tumor, Metastatic Solid Tumor.
What happened to similar drugs?
5 of 20 similar drugs in Locally Advanced Solid Tumor were approved
Approved (5) Terminated (1) Active (14)
Hype Score Breakdown
Clinical
9
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05118789 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Locally Advanced Solid Tumor